Skip to main content

AbbVie UK publishes 2018 transparency data; supporting collaboration of medical opinion towards advancing patient care and the development of new medicines

Press release   •   Jun 28, 2019 13:00 BST

Maidenhead, UK, 28th June 2019 – For the fourth year, AbbVie is pleased to see a rise in the number of doctors willing to consent to their transfers of value being made public.

Each year AbbVie discloses transfers of value to healthcare professionals and healthcare organisations to the Association of the British Pharmaceutical Industry (ABPI).

79 per cent (Nearly 4 in 5) of doctors who received sponsorship, fees or ‘in-kind’ support from AbbVie in 2018 opted-in for their individual data to be made public in the scheme.

AbbVie is encouraged that this marks increased confidence in AbbVie transparency from the medical profession. The collaboration of medical opinion is essential to advance patient care, gain insights into unmet medical needs and progress the development of new medicines. We believe interactions with healthcare professionals, healthcare organisations and patient organisations bring value to patient care.

AbbVie is proud of its collaboration with HCPs and HCOs which has contributed to delivering innovative medicines and has changed the way many diseases impact on patients’ lives. Open communication about these interactions increases understanding of this important collaboration.

Overall the total sum that AbbVie invests in working with and supporting UK healthcare organisations and doctors increased from 2018 compared to the year before with a rise of 31% per cent to £17.1m. Of this figure nearly 58 per cent is on the administration of clinical trials – demonstrating the enduring importance of the UK as a centre of excellence in the development of new medicines.

The full set of AbbVie data is available from the ABPI disclosure UK web portal at: http://www.disclosureuk.org.uk/

Please send data on file requests to UKMediaRelations@abbvie.com.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.